The first stop for professional medicines advice

Medicines planning

61 results

Applied filters

Primary care discussions: biosimilar insulin

30 April 2025Discussion about implementing biosimilar insulin in primary care: key considerations, hints, and tips for systems planning the transition. 10 June 2025.

Biosimilar and key generic medicines - April 2025 update

9 April 2025An update supporting implementation of biosimilar and key generic medicines for aflibercept, golimumab, nilotinib and ferric carboxymaltose.

What’s new in medicines mechanisms and governance PGDs

25 February 2025An update for those involved in medicines governance including managing PGDs and other medicine mechanisms in practice. 13 May 2025.
Registration required

New Product Evaluations

14 November 2024A list of new product evaluations that are freely available to NHS staff.

Using our annual medicines planning publication, Prescribing Outlook

28 October 2024Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.

Good governance when implementing ustekinumab biosimilar

2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for ustekinumab biosimilars

2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.

Monitoring and reviewing a PGD in practice

30 July 2024Monitoring and evaluating practice under a PGD and timely review of a PGD are important steps in the development process.

Writing a PGD

30 July 2024Writing a PGD is a multi-step process, requiring input from all members of the PGD development team.

Authorising and preparing to use a PGD

30 July 2024Once a PGD is written, there are steps to be completed before the PGD is used within an organisation.